High-dose Use of rhTPO in CIT Patients

Inclusion Criteria: * patients with malignant solid tumor * moderate or severe chemotherapy-induced thrombocytopenia, platelet counts less than 50×109/L * plan to use rhTPO * be willing to adopt appropriate methods of contraception during the study period and 8 weeks after the end of the study; women of childbearing age must undergo pregnancy tests (serum or urine) within 7 days before entering the study and the result must be negative * volunteer to participate in the study, sign the informed consent, and cooperate with good compliance Exclusion Criteria: * having other diseases that can lead to thrombocytopenia, such as aplastic anemia, myelodysplastic syndrome, leukemia, lymphoproliferative disease, immune thrombocytopenic purpura, thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, thyroid disease, liver cirrhosis, hypersplenism, etc. * using other non-chemotherapeutic drugs that can cause thrombocytopenia, such as sulfonamides, etc * with long-term wound or great worry of gastrointestinal bleeding * with venous thrombosis that need thrombolytic or anticoagulant therapy or high risk of venous thromboembolism * with infection requiring antibiotic treatment * History of immunodeficiency, including HIV positive, organ transplantation and other acquired/congenital immunodeficiency disorders * patients with Hepatitis B(except inactive carrier) or Hepatitis C * with serious heart disease or cerebrovascular disease * with heart failure or heart failur…